Vasoactive intestinal peptide: An anti-inflammatory neuropeptide

Psychoneuroimmunology, Two-Volume Set

Volumn 1, Issue , 2007, Pages 131-157

  Ganea, Doina ^a   Delgado, Mario ^b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34548423869     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088576-3/50009-5     Document Type: Chapter

References (233)

1. Abad C., Juarranz Y., Martinez C., Arranz A., Rosignoli F., Garcia-Gomez M., Leceta J., Gomariz R.P. cDNA array analysis of cytokines, chemokines, and receptors involved in the development of TNBS-induced colitis: homeostatic role of VIP. Inflamm. Bowel Dis. 2005, 11:674-684.
2. Abad C., Martinez C., Juarranz M.G., Arranz A., Leceta J., Delgado M., Gomariz R.P. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology 2003, 124:961-971.
3. Aliakbari J., Sreedharan S.P., Turck C.W., Goetzl E.J. Selective localization of vasoactive intestinal peptide and substance P in human eosinophils. Biochem. Biophys. Res. Commun. 1987, 148:1440-1445.
4. Andrew D.P., Chang M.S., McNinch J., Wathen S.T., Rihanek M., Tseng J., Spellberg J.P., Elias C.G.III STCP-1 (MDC) CC chemokine acts specifically on chronically activated Th2 lymphocytes and is produced by monocytes on stimulation with Th2 cytokines IL-4 and. J. Immunol. 1998, 161:5027-5038.
5. Asahina A., Hosoi J., Grabbe S., Granstein R.D. Modulation of Langerhans cell function by epidermal nerves. J. Allergy Clin. Immunol. 1995, 96:1178-1182.
6. Atreya R., Mudter J., Finotto S., Mullberg J., Jostock T., Wirtz S., Schutz M., Bartsch B., Holtmann M., Becker C., Strand D., Czaja J., Schlaak J.F., Lehr H.A., Autschbach F., Schurmann G., Nishimoto N., Yoshizaki K., Ito H., Kishimoto T., Galle P.R., Rose-John S., Neurath M.F. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and ex colitis in vivo. Nat. Med. 2000, 6:583-588.
7. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., Pulendran B., Palucka K. Immunobiology of dendritic cells. Annu. Rev. Immunol. 2000, 18:767-811.
8. Bartholdi D., Schwab M.E. Expression of proinflammatory cytokine and chemokine mRNA upon experimental spinal cord injury in mouse: an in situ hybridization study. Eur. J. Neurosci. 1997, 9:1422-1438.
9. Baumgartner J.D., Calandra T. Treatment of sepsis: past and future avenues. Drugs 1999, 57:127-132.
10. Behi M.E., Dubucquoi S., Lefranc D., Zephir H., De Seze J., Vermersch P., Prin L. New insights into cell responses involved in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol. Lett. 2005, 96:11-26.
11. Bellinger D.L., Lorton D., Brouxhon S., Felten S., Felten D.L. The significance of vasoactive intestinal polypeptide (VIP) in immunomodulation. Adv. Neuroimmunol. 1996, 6:5-27.
12. Bellinger D.L., Lorton D., Romano T.D., Olschowka J.A., Felten S.Y., Felten D.L. Neuropeptide innervation of lymphoid organs. Ann. N. Y. Acad. Sci. 1990, 594:17-33.
13. Bloem B.R., Irwin I., Buruma O.J., Haan J., Roos R.A., Tetrud J.W., Langston J.W. The MPTP model: versatile contributions to the treatment of idiopathic Parkinson's disease. J. Neurol. Sci. 1990, 97:273-293.
14. Bloom S.R., Christofides N.D., Delamarter J., Buell G., Kawashima E., Polak J.M. Diarrhoea in vipoma patients associated with cosecretion of a second active peptide (peptide histidine isoleucine) explained by single coding gene. Lancet 1983, 2:1163-1165.
15. Blumberg R.S., Strober W. Prospects for research in inflammatory bowel disease. JAMA 2001, 285:643-647.
16. Bonecchi R., Bianchi G., Bordignon P.P., D'Ambrosio D., Lang R., Borsatti A., Sozzani S., Allavena P., Gray P.A., Mantovani A., Sinigaglia F. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J. Exp. Med. 1998, 187:129-134.
17. Bynoe M.S., Evans J.T., Viret C., Janeway C.A.Jr. Epicutaneous immunization with autoantigenic peptides induces T suppressor cells that prevent experimental allergic encephalomyelitis. Immunity 2003, 19:317-328.
18. Calabresi P.A., Wilterdink J.L., Rogg J.M., Mills P., Webb A., Whartenby K.A. An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS. Neurology 2002, 58:314-317.
19. Calvo J.R., Molinero P., Jimenez J., Goberna R., Guerrero J.M. Interaction of vasoactive intestinal peptide (VIP) with rat lymphoid cells. Peptides 1986, 7:177-181.
20. Chao C.C., Hu S., Ehrlich L., Peterson P.K. Interleukin-1 and tumor necrosis factor-alpha synergistically mediate neurotoxicity: involvement of nitric oxide and of N-methyl-DasPARTate receptors. Brain Behav. Immun. 1995, 9:355-365.
21. Chatterjee T.K., Sharma R.V., Fisher R.A. Molecular cloning of a novel variant of the pituitary adenylate cyclaseactivating polypeptide (PACAP) receptor that stimulates calcium influx by activation o calcium channels. J. Biol. Chem. 1996, 271:32226-32232.
22. Chew L.J., Murphy D., Carter D.A. Alternatively polyadenylated vasoactive intestinal peptide mRNAs are differentially regulated at the level of stability. Mol. Endocrinol. 1994, 8:603-613.
23. Chorny A., Gonzalez-Rey E., Fernandez-Martin A., Pozo D., Ganea D., Delgado M. Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders. Proc. Natl. Acad. Sci. USA 2005, 102:13562-13567.
24. Chrivia J.C., Kwok R.P., Lamb N., Hagiwara M., Montminy M.R., Goodman R.H. Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature 1993, 365:855-859.
25. Cobb M.H. MAP kinase pathways. Prog. Biophys. Mol. Biol. 1999, 71:479-500.
26. Cohen J.L., Trenado A., Vasey D., Klatzmann D., Salomon B.L. CD4 (+) CD25 (+) immunoregulatory T cells: new therapeutics for graft-versus-host disease. J. Exp. Med. 2002, 196:401-406.
27. Cutz E., Chan W., Track N.S., Goth A., Said S.I. Release of vasoactive intestinal polypeptide in mast cells by histamine liberators. Nature 1978, 275:661-662.
28. Danner R.L., Elin R.J., Hosseini J.M., Wesley R.A., Reilly J.M., Parillo J.E. Endotoxemia in human septic shock. Chest 1991, 99:169-175.
29. Darnell J.E., Kerr I.M., Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264:1415-1421.
30. David S., Bouchard C., Tsatas O., Giftochristos N. Macrophages can modify the nonpermissive nature of the adult mammalian central nervous system. Neuron 1990, 5:463-469.
31. Decroly E., Wouters S., Di Bello C., Lazure C., Ruysschaert J.M., Seidah N.G. Identification of the paired basic convertases implicated in HIV gp160 processing based on in vitro assays and expression in CD4 (+) cell lines. J. Biol. Chem. 1996, 271:30442-30450.
32. Delgado M. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the MEKK1/ MEK4/JNK signaling pathway in endotoxin-activated micr. Biochem. Biophys. Res. Commun. 2002, 293:771-776.
33. Delgado M., Abad C., Martinez C., Juarranz M.G., Arranz A., Gomariz R.P., Leceta J. Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases. J. Mol. Med. 2002, 80:16-24.
34. Delgado M., Abad C., Martinez C., Leceta J., Gomariz R.P. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat. Med. 2001, 7:563-568.
35. Delgado M., Chorny A., Gonzalez-Rey E., Ganea D. Vasoactive intestinal peptide generates CD4+Cd25+ regulatory T cells in vivo. J. Leukoc. Biol. 2005, 78:1327-1338.
36. Delgado M., Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit interleukin-12 transcription by regulating nuclear factor kappaB activation. J. Biol. Chem. 1999, 274:31930-31940.
37. Delgado M., Ganea D. Inhibition of IFN-gamma-induced janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclaseactivating poly. J. Immunol. 2000, 165:3051-3057.
38. Delgado M., Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in LPS-stimulated macrophage. J. Neuroimmunol. 2000, 110:97-105.
39. Delgado M., Ganea D. Vasoactive intestinal pep-tide and pituitary adenylate cyclase-activating polypeptide inhibit antigen-induced apoptosis of mature T lymphocytes by inhibiting expression. J. Immunol. 2000, 164:1200-1210.
40. Delgado M., Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit T cell-mediated cytotoxicity by inhibiting Fas ligand expression. J. Immunol. 2000, 165:114-123.
41. Delgado M., Ganea D. Cutting edge: is vasoactive intestinal peptide a type 2 cytokine?. J. Immunol. 2001, 166:2907-2912.
42. Delgado M., Ganea D. Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vit vivo. J. Immunol. 2001, 167:966-975.
43. Delgado M., Ganea D. Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vit. J. Immunol. 2001, 167:966-975.
44. Delgado M., Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit expression of Fas ligand in activated T lymphocytes by regulating NF-kappa B, NF-AT, and early growth factors 2/3. J. Immunol. 2001, 166:1028-1040.
45. Delgado M., Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit nuclear factor-kappa B-dependent gene activation at multiple leve human monocytic cell line THP-1. J. Biol. Chem. 2001, 276:369-380.
46. Delgado M., Ganea D. VIP and PACAP inhibit Fas ligand-mediated bystander lysis by CD4 (+) T cells. J. Neuroimmunol. 2001, 112:78-88.
47. Delgado M., Ganea D. VIP and PACAP inhibit Fas ligand-mediated bystander lysis by CD4 (+) T cells. J. Neuroimmunol. 2001, 112:78-88.
48. Delgado M., Ganea D. Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation. FASEB J. 2003, 17:944-946.
49. Delgado M., Ganea D. Vasoactive intestinal peptide inhibits IL-8 production in human monocytes. Biochem. Biophys. Res. Commun. 2003, 301:825-832.
50. Delgado M., Ganea D. Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma. FASEB J. 2003, 17:1922-1924.
51. Delgado M., Gomariz R.P., Martinez C., Abad C., Leceta J. Anti-inflammatory properties of the type 1 and type 2 vasoactive intestinal peptide receptors: role in lethal endotoxic shock. Eur. J. Immunol. 2000, 30:3236-3246.
52. Delgado M., Gonzalez-Rey E., Ganea D. VIP/PACAP preferentially attract Th2 effectors through differential regulation of chemokine production by dendritic cells. FASEB J. 2004, 18:1453-1455.
53. Delgado M., Gonzalez-Rey E., Ganea D. The neuropeptide vasoactive intestinal peptide generates tolerogenic dendritic cells. J. Immunol. 2005, 175:7311-7324.
54. Delgado M., Jonakait G.M., Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia. Glia 2002, 39:148-161.
55. Delgado M., Leceta J., Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide promote in vivo generation of memory Th2 cells. FASEB J. 2002, 16:1844-1846.
56. Delgado M., Leceta J., Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia. J. Leukoc. Biol. 2003, 73:155-164.
57. Delgado M., Leceta J., Gomariz R.P., Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclaseactivating polypeptide stimulate the induction of Th2 responses by up-regulating B7.2 expression. J. Immunol. 1999, 163:3629-3635.
58. Delgado M., Martinez C., Johnson M.C., Gomariz R.P., Ganea D. Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes. J. Neuroimmunol. 1996, 68:27-38.
59. Delgado M., Martinez C., Pozo D., Calvo J.R., Leceta J., Ganea D., Gomariz R.P. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition TNF-alpha and IL-6. J. Immunol. 1999, 162:1200-1205.
60. Delgado M., Munoz-Elias E.J., Gomariz R.P., Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo stud. J. Immunol. 1999, 162:1707-1716.
61. Delgado M., Munoz-Elias E.J., Gomariz R.P., Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by i NF-kappa B and IFN regulatory factor 1 activation. J. Immunol. 1999, 162:4685-4696.
62. Delgado M., Munoz-Elias E.J., Gomariz R.P., Ganea D. VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells. J. Neuroimmunol. 1999, 96:167-181.
63. Delgado M., Munoz-Elias E.J., Kan Y., Gozes I., Fridkin M., Brenneman D.E., Gomariz R.P., Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulat factor-kB and cAMP response element-binding protein/c-Jun. J. Biol. Chem. 1998, 273:31427-31436.
64. Delgado M., Pozo D., Martinez C., Leceta J., Calvo J.R., Ganea D., Gomariz R.P. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-alpha production by macrophages: in vitro a vivo studies. J. Immunol. 1999, 162:2358-2367.
65. Delgado M., Reduta A., Sharma V., Ganea D. VIP/ PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4 (+) T cells. J. Leukoc. Biol. 2004, 75:1122-1130.
66. Delgado M., Sun W., Leceta J., Ganea D. VIP and PACAP differentially regulate the costimulatory activity of resting and activated macrophages through the modulation of B7.1 and B7.2 expression. J. Immunol. 1999, 163:4213-4223.
67. Delporte C., Poloczek P., de Neef P., Vertongen P., Ciccarelli E., Svoboda M., Herchuelz A., Winand J., Robberecht P. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide stimulate two signaling pathways in CHO cells stably transfected selective type I PACAP receptor. Mol. Cell. Endocrinol. 1995, 107:71-76.
68. Dewit D., Gourlet P., Amraoui Z., Vertongen P., Willems F., Robberecht P., Goldman M. The vasoactive intestinal peptide analogue RO25-1553 inhibits the production of TNF and IL-12 by LPS-activated monocytes. Immunol. Lett. 1998, 60:57-60.
69. Dey R.D., Shannon W.A., Said S.I. Localization of VIP-immunoreactive nerves in airways and pulmonary vessels of dogs, cats, and human subjects. Cell Tissue Res. 1981, 220:231-238.
70. Ding M., St Pierre B.A., Parkinson J.F., Medberry P., Wong J.L., Rogers N.E., Ignarro L.J., Merrill J.E. Inducible nitric-oxide synthase and nitric oxide production in human fetal astrocytes and microglia. A kinetic analysis. J. Biol. Chem. 1997, 272:11327-11335.
71. Evans C.H. Nitric oxide: what role does it play in inflammation and tissue destruction?. Agents Actions SUPPL. 1995, 47:107-116.
72. Fahrig T., Gerlach I., Horvath E. A synthetic derivative of the natural product rocaglaol is a potent inhibitor of cytokinemediated signaling and shows neuroprotective activity in vitro and in models of Parkinson's disease and traumatic brain injury. Mol. Pharmacol. 2005, 67:1544-1555.
73. Feldmann M. What is the mechanism of action of antitumour necrosis factor-alpha antibody in rheumatoid arthritis?. Int. Arch. Allergy Immunol. 1996, 111:362-365.
74. Felten D.L. Direct innervation of lymphoid organs: substrate for neurotransmitter signaling of cells of the immune system. Neuropsychobiology 1993, 28:110-112.
75. Fernandez-Martin A., Gonzalez-Rey E., Chorny A., Ganea D., Delgado M. Vasoactive intestinal peptide induces regulatory T cells during experimental autoimmune encephalomyelitis. Eur. J. Immunol. 2006, 36:318-326.
76. Fink T., Weihe E. Multiple neuropeptides in nerves supplying mammalian lymph nodes: messenger candidates for sensory and autonomic neuroimmunomodulation?. Neurosci. Lett. 1988, 90:39-44.
77. Frank M., Wolburg H. Cellular reactions at the lesion site after crushing of the rat optic nerve. Glia 1996, 16:227-240.
78. Furness J.B., Costa M. Types of nerves in the enteric nervous system. Neuroscience 1980, 5:1-20.
79. Fuss I.J., Marth T., Neurath M.F., Pearlstein G.R., Jain A., Strober W. Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology 1999, 117:1078-1088.
80. Ganea D. Regulatory effects of vasoactive intestinal peptide on cytokine production in central and peripheral lymphoid organs. Adv. Neuroimmunol. 1996, 6:61-74.
81. Ganea D., Rodriguez R., Delgado M. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: players in innate and adaptive immunity. Cell. Mol. Biol. (Noisy-le-grand) 2003, 49:127-142.
82. Gerritsen M.E., Williams A.J., Neish A.S., Moore S., Shi Y., Collins T. CREB-binding protein/p300 are transcriptional coactivators of p65. Proc. Natl. Acad. Sci. USA 1997, 94:2927-2932.
83. Giulian D., Chen J., Ingeman J.E., George J.K., Noponen M. The role of mononuclear phagocytes in wound healing after traumatic injury to adult mammalian brain. J. Neurosci. 1989, 9:4416-4429.
84. Glauser M.P., Heumann D., Baumgartner J.D., Cohen J. Pathogenesis and potential strategies for prevention and treatment of septic shock: an update. Clin. Infect. Dis. 1994, 18(Suppl 2):S205-S216.
85. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2001, 2:492-501.
86. Goetzl E.J., Sreedharan S.P., Turck C.W. Structurally distinctive vasoactive intestinal peptides from rat basophilic leukemia cells. J. Biol. Chem. 1988, 263:9083-9086.
87. Goetzl E.J., Voice J.K., Shen S., Dorsam G., Kong Y., West K.M., Morrison C.F., Harmar A.J. Enhanced delayedtype hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC (2) receptor for vasoactive intestinal. Proc. Natl. Acad. Sci. USA 2001, 98:13854-13859.
88. Goldman P.S., Tran V.K., Goodman R.H. The multifunctional role of the co-activator CBP in transcriptional regulation. Recent Prog. Horm. Res. 1997, 52:103-119.
89. Gomariz R.P., Arranz A., Abad C., Torroba M., Martinez C., Rosignoli F., Garcia-Gomez M., Leceta J., Juarranz Y. Time-course expression of Toll-like receptors 2 and 4 in inflammatory bowel disease and homeostatic effect of VIP. J. Leukoc. Biol. 2005, 78:491-502.
90. Gomariz R.P., De La F.M., Hernanz A., Leceta J. Occurrence of vasoactive intestinal peptide (VIP) in lymphoid organs from rat and mouse. Ann. N. Y. Acad. Sci. 1992, 650:13-18.
91. Gomariz R.P., Leceta J., Garrido E., Garrido T., Delgado M. Vasoactive intestinal peptide (VIP) mRNA expression in rat T and B lymphocytes. Regul. Pept. 1994, 50:177-184.
92. Gomariz R.P., Martinez C., Abad C., Leceta J., Delgado M. Immunology of VIP: a review and therapeutical perspectives. Curr. Pharm. Des. 2001, 7:89-111.
93. Gonzalez-Rey E., Fernandez-Martin A., Chorny A., Delgado M. Vasoactive intestinal peptide induces CD4+CD25+ T regulatory cells with therapeutic effect in collagen-induced arthritis. Arthritis Rheum. 2006, 54:864-876.
94. Gonzalez-Rey E., Fernandez-Martin A., Chorny A., Martin J., Pozp D., Ganea D., Delgado M. Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis. Am. J. Pathol. 2006, 168:1179-1188.
95. Gonzalez-Scarano F., Baltuch G. Microglia as mediators of inflammatory and degenerative diseases. Annu. Rev. Neurosci. 1999, 22:219-240.
96. Gozes I., Brenneman D.E. A new concept in the pharmacology of neuroprotection. J. Mol. Neurosci. 2000, 14:61-68.
97. Gregori S., Casorati M., Amuchastegui S., Smiroldo S., Davalli A.M., Adorini L. Regulatory T cells induced by 1 alpha, 25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J. Immunol. 2001, 167:1945-1953.
98. Grider J.R., Jin J.G. Vasoactive intestinal peptide release and L-citrulline production from isolated ganglia of the myenteric plexus: evidence for regulation of vasoactive intesti release by nitric oxide. Neuroscience 1993, 54:521-526.
99. Grimm M.C., Newman R., Hassim Z., Cuan N., Connor S.J., Le Y., Wang J.M., Oppenheim J.J., Lloyd A.R. Cutting edge: vasoactive intestinal peptide acts as a potent suppressor of inflammation in vivo by trans-deactivating chemokine receptors. J. Immunol. 2003, 171:4990-4994.
100. Grinninger C., Wang W., Oskoui K.B., Voice J.K., Goetzl E.J. A natural variant type II G protein-coupled receptor for vasoactive intestinal peptide with altered function. J. Biol. Chem. 2004, 279:40259-40262.
101. Grunblatt E., Mandel S., Youdim M.B. MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson's disease: neuroprotective strategies. J. Neurol. 2000, 247(Suppl 2). I95-II102.
102. Guerrero J.M., Prieto J.C., Elorza F.L., Ramirez R., Goberna R. Interaction of vasoactive intestinal peptide with human blood mononuclear cells. Mol. Cell. Endocrinol. 1981, 21:151-160.
103. Hanauer S.B., Present D.H. The state of the art in the management of inflammatory bowel disease. Rev. Gastroenterol. Disord. 2003, 3:81-92.
104. Harmar A.J., Arimura A., Gozes I., Journot L., Laburthe M., Pisegna J.R., Rawlings S.R., Robberecht P., Said S.I., Sreedharan S.P., Wank S.A., Waschek J.A. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclaseactivating polypeptide. Pharmacol. Rev. 1998, 50:265-270.
105. Hoffmann P., Ermann J., Edinger M., Fathman C.G., Strober S. Donor-type CD4 (+) CD25 (+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J. Exp. Med. 2002, 196:389-399.
106. Howard L.M., Miller S.D. Immunotherapy targeting the CD40/CD154 costimulatory pathway for treatment of autoimmune disease. Autoimmunity 2004, 37:411-418.
107. Imai T., Nagira M., Takagi S., Kakizaki M., Nishimura M., Wang J., Gray P.W., Matsushima K., Yoshie O. Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage- chemokine. Int. Immunol. 1999, 11:81-88.
108. Itoh N., Obata K., Yanaihara N., Okamoto H. Human preprovasoactive intestinal polypeptide contains a novel PHI-27-like peptide, PHM-27. Nature 1983, 304:547-549.
109. Jackson-Lewis V., Smeyne R.J. MPTP and SNpc DA neuronal vulnerability: role of dopamine, superoxide and nitric oxide in neurotoxicity. Minireview. Neurotox. Res. 2005, 7:193-202.
110. Janknecht R., Nordheim A. MAP kinase-dependent transcriptional coactivation by Elk-1 and its cofactor CBP. Biochem. Biophys. Res. Commun. 1996, 228:831-837.
111. Jenner P., Olanow C.W. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 1996, 47:S161-S170.
112. Jiang X., Jing H., Ganea D. VIP and PACAP downregulate CXCL10 (IP-10) and up-regulate CCL22 (MDC) in spleen cells. J. Neuroimmunol. 2002, 133:81-94.
113. Joosten L.A., Lubberts E., Helsen M.M., van den Berg W.B. Dual role of IL-12 in early and late stages of murine collagen type II arthritis. J. Immunol. 1997, 159:4094-4102.
114. Juarranz M.G., Santiago B., Torroba M., Gutierrez-Canas I., Palao G., Galindo M., Abad C., Martinez C., Leceta J., Pablos J.L., Gomariz R.P. Vasoactive intestinal peptide modulates proinflammatory mediator synthesis in osteoarthritic and rheumatoid synovial cells. Rheumatology (Oxford 2004, ) 43:416-422.
115. Kaltreider H.B., Ichikawa S., Byrd P.K., Ingram D.A., Kishiyama J.L., Sreedharan S.P., Warnock M.L., Beck J.M., Goetzl E.J. Upregulation of neuropeptides and neuropeptide receptors in a murine model of immune inflammation in lung parenchyma. Am. J. Respir. Cell Mol. Biol. 1997, 16:133-144.
116. Kamei Y., Xu L., Heinzel T., Torchia J., Kurokawa R., Gloss B., Lin S.C., Heyman R.A., Rose D.W., Glass C.K., Rosenfeld M.G. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 1996, 85:403-414.
117. Kato H., Ito A., Kawanokuchi J., Jin S., Mizuno T., Ojika K., Ueda R., Suzumura A. Pituitary adenylate cyclaseactivating polypeptide (PACAP) ameliorates experimental autoimmune encephalomyelitis by suppressing the functions of antigen presen. Mult. Scler. 2004, 10:651-659.
118. Killestein J., Kalkers N.F., Polman C.H. Glutamate inhibition in MS: the neuroprotective properties of riluzole. J. Neurol. Sci. 2005, 233:113-115.
119. Kim S.U., de Vellis J. Microglia in health and disease. J. Neurosci. Res. 2005, 81:302-313.
120. Kim W.K., Ganea D., Jonakait G.M. Inhibition of microglial CD40 expression by pituitary adenylate cyclaseactivating polypeptide is mediated by interleukin-10. J. Neuroimmunol. 2002, 126:16-24.
121. Kim W.K., Kan Y., Ganea D., Hart R.P., Gozes I., Jonakait G.M. Vasoactive intestinal peptide and pituitary adenyl cyclase-activating polypeptide inhibit tumor necrosis factoralpha production in injured spinal cord and in microglia via a cAMP-dependent pathway. J. Neurosci. 2000, 20:3622-3630.
122. Kohm A.P., Carpentier P.A., Anger H.A., Miller S.D. Cutting edge: CD4+CD25+ regulatory T cells suppress antigenspecific autoreactive immune responses and central nervous system inflammation during active expe autoimmune encephalomyelitis. J. Immunol. 2002, 169:4712-4716.
123. Kwok R.P., Lundblad J.R., Chrivia J.C., Richards J.P., Bachinger H.P., Brennan R.G., Roberts S.G., Green M.R., Goodman R.H. Nuclear protein CBP is a coactivator for the transcription factor CREB. Nature 1994, 370:223-226.
124. Lara-Marquez M.L., O'Dorisio M.S., Karacay B. Vasoactive intestinal peptide (VIP) receptor type 2 (VPAC2) is the predominant receptor expressed in human thymocytes. Ann. N.Y. Acad. Sci. 2000, 921:45-54.
125. Lara-Marquez M., O'Dorisio M., O'Dorisio T., Shah M., Karacay B. Selective gene expression and activationdependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells. J. Immunol. 2001, 166:2522-2530.
126. Laskin D.L., Pendino K.J. Macrophages and inflammatory mediators in tissue injury. Annu. Rev. Pharmacol. Toxicol. 1995, 35:655-677.
127. Leceta J., Martinez C., Delgado M., Garrido E., Gomariz R.P. Expression of vasoactive intestinal peptide in lymphocytes: a possible endogenous role in the regulation of the immune system. Adv. Neuroimmunol. 1996, 6:29-36.
128. Leceta J., Martinez M.C., Delgado M., Garrido E., Gomariz R.P. Lymphoid cell subpopulations containing vasoactive intestinal peptide in the rat. Peptides 1994, 15:791-797.
129. Lee C.M., Kumar R.K., Lubowski D.Z., Burcher E. Neuropeptides and nerve growth in inflammatory bowel diseases: a quantitative immunohistochemical study. Dig. Dis. Sci. 2002, 47:495-502.
130. Lee S.C., Liu W., Dickson D.W., Brosnan C.F., Berman J.W. Cytokine production by human fetal microglia and astrocytes. Differential induction by lipopolysaccharide and IL-1 beta. J. Immunol. 1993, 150:2659-2667.
131. Levings M.K., Gregori S., Tresoldi E., Cazzaniga S., Bonini C., Roncarolo M.G. Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. Blood 2005, 105:1162-1169.
132. Lipton J.M., Catania A. Anti-inflammatory actions of the neuroimmunomodulator alpha-MSH. Immunol. Today 1997, 18:140-145.
133. Lipton S.A., Singel D.J., Stamler J.S. Nitric oxide in the central nervous system. Prog. Brain Res. 1994, 103:359-364.
134. Loetscher P., Uguccioni M., Bordoli L., Baggiolini M., Moser B., Chizzolini C., Dayer J.M. CCR5 is characteristic of Th1 lymphocytes. Nature 1998, 391:344-345.
135. Lundberg J.M., Hokfelt T., Kewenter J., Pettersson G., Ahlman H., Edin R., Dahlstrom A., Nilsson G., Terenius L., Uvnas-Wallensten K., Said S. Substance P-, VIP-, and enkephalin-like immunoreactivity in the human vagus nerve. Gastroenterology 1979, 77:468-471.
136. Luster A.D. Chemokines-chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 1998, 338:436-445.
137. Lygren I., Revhaug A., Burhol P.G., Giercksky K.E., Jenssen T.G. Vasoactive intestinal polypeptide and somatostatin in leucocytes. Scand. J. Clin. Lab. Invest. 1984, 44:347-351.
138. Ma X., Aste-Amezaga M., Gri G., Gerosa F., Trinchieri G. Immunomodulatory functions and molecular regulation of IL-12. Chem. Immunol. 1997, 68:1-22.
139. Martin E., Nathan C., Xie Q.W. Role of interferon regulatory factor 1 in induction of nitric oxide synthase. J. Exp. Med. 1994, 180:977-984.
140. Martinez C., Abad C., Delgado M., Arranz A., Juarranz M.G., Rodriguez-Henche N., Brabet P., Leceta J., Gomariz R.P. Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor. Proc. Natl. Acad. Sci. USA 2002, 99:1053-1058.
141. Martinez C., Delgado M., Abad C., Gomariz R.P., Ganea D., Leceta J. Regulation of VIP production and secretion by murine lymphocytes. J. Neuroimmunol. 1999, 93:126-138.
142. Martinez C., Delgado M., Pozo D., Leceta J., Calvo J.R., Ganea D., Gomariz R.P. VIP and PACAP enhance IL-6 release and mRNA levels in resting peritoneal macrophages: in vitro and in vivo studies. J. Neuroimmunol. 1998, 85:155-167.
143. Martinez C., Juarranz Y., Abad C., Arranz A., Miguel B.G., Rosignoli F., Leceta J., Gomariz R.P. Analysis of the role of the PAC1 receptor in neutrophil recruitment, acutephase response, and nitric oxide production in septic shock. J. Leukoc. Biol. 2005, 77:729-738.
144. Matsuyama H., Unno T., El Mahmoudy A.M., Komori S., Kobayashi H., Thapaliya S., Takewaki T. Peptidergic and nitrergic inhibitory neurotransmissions in the hamster jejunum: regulation of vasoactive intestinal peptide release by nitric oxide. Neuroscience 2002, 110:779-788.
145. Mauri C., Williams R.O., Walmsley M., Feldmann M. Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis. Eur. J. Immunol. 1996, 26:1511-1518.
146. McCulloch D.A., Lutz E.M., Johnson M.S., MacKenzie C.J., Mitchell R. Differential activation of phospholipase D by VPAC and PAC1 receptors. Ann. N. Y. Acad. Sci. 2000, 921:175-185.
147. McCulloch D.A., Lutz E.M., Johnson M.S., Robertson D.N., MacKenzie C.J., Holland P.J., Mitchell R. ADPribosylation factor-dependent phospholipase D activation by VPAC receptors and a PAC (1) receptor splice variant. Mol. Pharmacol. 2001, 59:1523-1532.
148. McCulloch D.A., MacKenzie C.J., Johnson M.S., Robertson D.N., Holland P.J., Ronaldson E., Lutz E.M., Mitchell R. Additional signals from VPAC/PAC family receptors. Biochem. Soc. Trans. 2002, 30:441-446.
149. McManus C.M., Brosnan C.F., Berman J.W. Cytokine induction of MIP-1 alpha and MIP-1 beta in human fetal microglia. J. Immunol. 1998, 160:1449-1455.
150. Menges M., Rossner S., Voigtlander C., Schindler H., Kukutsch N.A., Bogdan C., Erb K., Schuler G., Lutz M.B. Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. J. Exp. Med. 2002, 195:15-21.
151. Mezzapesa D.M., Rovaris M., Filippi M. Glatiramer acetate in multiple sclerosis. Expert Rev. Neurother. 2005, 5:451-458.
152. Minghetti L., Ajmone-Cat M.A., De Berardinis M.A., De Simone R. Microglial activation in chronic neurodegenerative diseases: roles of apoptotic neurons and chronic stimulation. Brain Res. Brain Res. Rev. 2005, 48:251-256.
153. Miyaura H., Iwata M. Direct and indirect inhibition of Th1 development by progesterone and glucocorticoids. J. Immunol. 2002, 168:1087-1094.
154. Mizuno Y., Ikebe S., Hattori N., Nakagawa-Hattori Y., Mochizuki H., Tanaka M., Ozawa T. Role of mitochondria in the etiology and pathogenesis of Parkinson's disease. Biochim. Biophys. Acta 1995, 1271:265-274.
155. Moreno-Flores M.T., Bovolenta P., Nieto-Sampedro M. Polymorphonuclear leukocytes in brain parenchyma after injury and their interaction with purified astrocytes in culture. Glia 1993, 7:146-157.
156. Morganti-Kossmann M.C., Rancan M., Stahel P.F., Kossmann T. Inflammatory response in acute traumatic brain injury: a double-edged sword. Curr. Opin. Crit. Care 2002, 8:101-105.
157. Mosimann B.L., White M.V., Hohman R.J., Goldrich M.S., Kaulbach H.C., Kaliner M.A. Substance P, calcitonin gene-related peptide, and vasoactive intestinal peptide increase in nasal secretions after allergen challenge in atopic patients. J. Allergy Clin. Immunol. 1993, 92:95-104.
158. Murdoch D., Lyseng-Williamson K.A. Subcutaneous recombinant interferon-beta-1a (Rebif ( (R) ) ) : a review of its use in relapsing-remitting multiple sclerosis. Drugs 2005, 65:1295-1312.
159. Murray M., Kim D., Liu Y., Tobias C., Tessler A., Fischer I. Transplantation of genetically modified cells contributes to repair and recovery from spinal injury. Brain Res. Brain Res. Rev. 2002, 40:292-300.
160. Nagatsu T., Sawada M. Inflammatory process in Parkinson's disease: role for cytokines. Curr. Pharm. Des. 2005, 11:999-1016.
161. Nelson P.T., Soma L.A., Lavi E. Microglia in diseases of the central nervous system. Ann. Med. 2002, 34:491-500.
162. Neurath M.F., Weigmann B., Finotto S., Glickman J., Nieuwenhuis E., Iijima H., Mizoguchi A., Mizoguchi E., Mudter J., Galle P.R., Bhan A., Autschbach F., Sullivan B.M., Szabo S.J., Glimcher L.H., Blumberg R.S. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J. Exp. Med. 2002, 195:1129-1143.
163. Nguyen V.T., Benveniste E.N. Critical role of tumor necrosis factor-alpha and NF-kappa B in interferon-gamma-induced CD40 expression in microglia/macrophages. J. Biol. Chem. 2002, 277:13796-13803.
164. Nieber K., Baumgarten C.R., Rathsack R., Furkert J., Oehme P., Kunkel G. Substance P and beta-endorphin-like immunoreactivity in lavage fluids of subjects with and without allergic asthma. J. Allergy Clin. Immunol. 1992, 90:646-652.
165. Nikolaus S., Raedler A., Kuhbacker T., Sfikas N., Folsch U.R., Schreiber S. Mechanisms in failure of infliximab for Crohn's disease. Lancet 2000, 356:1475-1479.
166. O'Dorisio M.S., Hermina N.S., O'Dorisio T.M., Balcerzak S.P. Vasoactive intestinal polypeptide modulation of lymphocyte adenylate cyclase. J. Immunol. 1981, 127:2551-2554.
167. O'Dorisio M.S., O'Dorisio T.M., Cataland S., Balcerzak S.P. Vasoactive intestinal polypeptide as a biochemical marker for polymorphonuclear leukocytes. J. Lab. Clin. Med. 1980, 96:666-672.
168. O'Garra A. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 1998, 8:275-283.
169. Ohmori Y., Hamilton T.A. Cooperative interaction between interferon (IFN) stimulus response element and kappa B sequence motifs controls IFN gamma-and lipopolysaccharidestimulated tra from the murine IP-10 promoter. J. Biol. Chem. 1993, 268:6677-6688.
170. Ottaway C.A., Bernaerts C., Chan B., Greenberg G.R. Specific binding of vasoactive intestinal peptide to human circulating mononuclear cells. Can. J. Physiol. Pharmacol. 1983, 61:664-671.
171. Ottaway C.A., Greenberg G.R. Interaction of vasoactive intestinal peptide with mouse lymphocytes: specific binding and the modulation of mitogen responses. J. Immunol. 1984, 132:417-423.
172. Owens T. The enigma of multiple sclerosis: inflammation and neurodegeneration cause heterogeneous dysfunction and damage. Curr. Opin. Neurol. 2003, 16:259-265.
173. Pankhaniya R., Jabrane-Ferrat N., Gaufo G.O., Sreedharan S.P., Dazin P., Kaye J., Goetzl E.J. Vasoactive intestinal peptide enhancement of antigen-induced differentiation of a cultured line of mouse thymocytes. FASEB J. 1998, 12:119-127.
174. Parrillo J.E. Pathogenetic mechanisms of septic shock. N. Engl. J. Med. 1993, 328:1471-1477.
175. Pease J.E., Horuk R. CCR1 antagonists in clinical development. Expert Opin. Investig. Drugs 2005, 14:785-796.
176. Peterson P.K., Hu S., Salak-Johnson J., Molitor T.W., Chao C.C. Differential production of and migratory response to beta chemokines by human microglia and astrocytes. J. Infect. Dis. 1997, 175:478-481.
177. Piemonti L., Monti P., Sironi M., Fraticelli P., Leone B.E., Dal Cin E., Allavena P., Di C.V. Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J. Immunol. 2000, 164:4443-4451.
178. Pisegna J.R., Moody T.W., Wank S.A. Differential signaling and immediate-early gene activation by four splice variants of the human pituitary adenylate cyclase-activating polypeptide receptor (h. N. Y. Acad. Sci. 1996, 805:54-64.
179. Przedborski S., Jackson-Lewis V., Djaldetti R., Liberatore G., Vila M., Vukosavic S., Almer G. The parkinsonian toxin MPTP: action and mechanism. Restor. Neurol. Neurosci. 2000, 16:135-142.
180. Pyo H., Jou I., Jung S., Hong S., Joe E.H. Mitogenactivated protein kinases activated by lipopolysaccharide and beta-amyloid in cultured rat microglia. Neuroreport 1998, 9:871-874.
181. Qin S., Rottman J.B., Myers P., Kassam N., Weinblatt M., Loetscher M., Koch A.E., Moser B., Mackay C.R. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J. Clin. Invest. 1998, 101:746-754.
182. Rameshwar P., Gascon P., Oh H.S., Denny T.N., Zhu G., Ganea D. Vasoactive intestinal peptide (VIP) inhibits the proliferation of bone marrow progenitors through the VPAC1 receptor. Exp. Hematol. 2002, 30:1001-1009.
183. Ranger A.M., Das M.P., Kuchroo V.K., Glimcher L.H. B7-2 (CD86) is essential for the development of IL-4-producing T cells. Int. Immunol. 1996, 8:1549-1560.
184. Reddy J., Illes Z., Zhang X., Encinas J., Pyrdol J., Nicholson L., Sobel R.A., Wucherpfennig K.W., Kuchroo V.K. Myelin proteolipid protein-specific CD4+CD25+ regulatory cells mediate genetic resistance to experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 2004, 101:15434-15439.
185. Reubi J.C. In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. Clinical implications. Ann. N. Y. Acad. Sci. 2000, 921:1-25.
186. Rollins B.J. Chemokines. Blood 1997, 90:909-928.
187. Rossi D., Zlotnik A. The biology of chemokines and their receptors. Annu. Rev. Immunol. 2000, 18:217-242.
188. Said S.I. Vasoactive intestinal peptide. J. Endocrinol. Invest. 1986, 9:191-200.
189. Sallusto F., Lanzavecchia A., Mackay C.R. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol. Today 1998, 19:568-574.
190. Schwartz M., Moalem G., Leibowitz-Amit R., Cohen I.R. Innate and adaptive immune responses can be beneficial for CNS repair. Trends Neurosci. 1999, 22:295-299.
191. Segal B.M. CNS chemokines, cytokines, and dendritic cells in autoimmune demyelination. J. Neurol. Sci. 2005, 228:210-214.
192. Sharma V., Delgado M., Ganea D. Granzyme B, a new placer in activation-induced cell death, is down-regulated by vasoactive intestinal peptide in Th2 but not Th1 effector. J. Immunol. 2006, 176:97-110.
193. Sims S.H., Cha Y., Romine M.F., Gao P.Q., Gottlieb K., Deisseroth A.B. A novel interferon-inducible domain: structural and functional analysis of the human interferon regulatory factor 1 gene promoter. Mol. Cell. Biol. 1993, 13:690-702.
194. Smyth M.J. Fas ligand-mediated bystander lysis of syngeneic cells in response to an allogeneic stimulus. J. Immunol. 1997, 158:5765-5772.
195. Spengler D., Waeber C., Pantaloni C., Holsboer F., Bockaert J., Seeburg P.H., Journot L. Differential signal transduction by five splice variants of the PACAP receptor. Nature 1993, 365:170-175.
196. Stalder T., Hahn S., Erb P. Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity. J. Immunol. 1994, 152:1127-1133.
197. Steinman L. Assessment of animal models for MS and demyelinating disease in the design of rational therapy. Neuron 1999, 24:511-514.
198. Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat. Rev. Drug Discov. 2005, 4:510-518.
199. Steinman R.M. The control of immunity and tolerance by dendritic cell. Pathol. Biol. (Paris 2003, ) 51:59-60.
200. Stoll G., Jander S., Schroeter M. Detrimental and beneficial effects of injury-induced inflammation and cytokine expression in the nervous system. Adv. Exp. Med. Biol. 2002, 513:87-113.
201. Streit W.J., Graeber M.B., Kreutzberg G.W. Functional plasticity of microglia: a review. Glia 1988, 1:301-307.
202. Streit W.J., Semple-Rowland S.L., Hurley S.D., Miller R.C., Popovich P.G., Stokes B.T. Cytokine mRNA pro-files in contused spinal cord and axotomized facial nucleus suggest a beneficial role for inflammation and gliosis. Exp. Neurol. 1998, 152:74-87.
203. Tabarowski Z., Gibson-Berry K., Felten S.Y. Noradrenergic and peptidergic innervation of the mouse femur bone marrow. Acta Histochem. 1996, 98:453-457.
204. Takeba Y., Suzuki N., Kaneko A., Asai T., Sakane T. Evidence for neural regulation of inflammatory synovial cell functions by secreting calcitonin gene-related peptide and vasoactive intestinal peptide in patie rheumatoid arthritis. Arthritis Rheum. 1999, 42:2418-2429.
205. Taupin V., Toulmond S., Serrano A., Benavides J., Zavala F. Increase in IL-6, IL-1 and TNF levels in rat brain following traumatic lesion. influence of pre-and post-traumatic treatment with Ro 5 4864, a peripheral-typ benzodiazepine ligand. J. Neuroimmunol 1993, 42:177-185.
206. Trenado A., Charlotte F., Fisson S., Yagello M., Klatzmann D., Salomon B.L., Cohen J.L. Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versusleukemia. J. Clin. Invest. 2003, 112:1688-1696.
207. Tuncel N., Tore F., Sahinturk V., Ak D., Tuncel M. Vasoactive intestinal peptide inhibits degranulation and changes granular content of mast cells: a potential therapeutic strategy in controlling septic shock. Peptides 2000, 21:81-89.
208. van Deuren M., Dofferhoff A.S., van der Meer J.W. Cytokines and the response to infection. J. Pathol. 1992, 168:349-356.
209. Van Rampelbergh J., Poloczek P., Francoys I., Delporte C., Winand J., Robberecht P., Waelbroeck M. The pituitary adenylate cyclase activating polypeptide (PACAP I) and VIP (PACAP II VIP1) receptors stimulate inositol phosphate synthesis in transfected CHO c interaction with different G proteins. Biochim. Biophys. Acta 1997, 1357:249-255.
210. Van Snick J. Interleukin-6: an overview. Annu. Rev. Immunol. 1990, 8:253-278.
211. Vassalli P. The pathophysiology of tumor necrosis factors. Annu. Rev. Immunol. 1992, 10:411-452.
212. Vassiliou E., Jiang X., Delgado M., Ganea D. Th2 lymphocytes secrete functional VIP upon antigen stimulation. Arch. Physiol. Biochem. 2001, 109:365-368.
213. Viglietta V., Baecher-Allan C., Weiner H.L., Hafler D.A. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 2004, 199:971-979.
214. Voice J., Donnelly S., Dorsam G., Dolganov G., Paul S., Goetzl E.J. c-Maf and JunB mediation of Th2 differentiation induced by the type 2 G protein-coupled receptor (VPAC2) for vasoactive intestinal peptide. J. Immunol. 2004, 172:7289-7296.
215. Voice J.K., Dorsam G., Lee H., Kong Y., Goetzl E.J. Allergic diathesis in transgenic mice with constitutive T cell expression of inducible vasoactive intestinal peptide receptor. FASEB J. 2001, 15:2489-2496.
216. Voice J.K., Grinninger C., Kong Y., Bangale Y., Paul S., Goetzl E.J. Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor trans. J. Immunol. 2003, 170:308-314.
217. Wakkach A., Fournier N., Brun V., Breittmayer J.P., Cottrez F., Groux H. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity 2003, 18:605-617.
218. Walmsley M., Katsikis P.D., Abney E., Parry S., Williams R.O., Maini R.N., Feldmann M. Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum. 1996, 39:495-503.
219. Wang H.Y., Jiang X., Gozes I., Fridkin M., Brenneman D.E., Ganea D. Vasoactive intestinal peptide inhibits cytokine production in T lymphocytes through cAMP-dependent and cAMP-independent mechanisms. Regul. Pept. 1999, 84:55-67.
220. Wang H.Y., Jiang X.M., Ganea D. The neuropeptides VIP and PACAP inhibit IL-2 transcription by decreasing c-Jun and increasing JunB expression in T cells. J. Neuroimmunol. 2000, 104:68-78.
221. Wang R., Rogers A.M., Ratliff T.L., Russell J.H. CD95-dependent bystander lysis caused by CD4+ T helper 1 effectors. J. Immunol. 1996, 157:2961-2968.
222. Weinstock J.V., Blum A.M. Detection of vasoactive intestinal peptide and localization of its mRNA within granulomas of murine schistosomiasis. Cell. Immunol. 1990, 125:291-300.
223. Wershil B.K., Turck C.W., Sreedharan S.P., Yang J., An S., Galli S.J., Goetzl E.J. Variants of vasoactive intestinal peptide in mouse mast cells and rat basophilic leukemia cells. Cell. Immunol. 1993, 151:369-378.
224. Wheeler R.D., Owens T. The changing face of cytokines in the brain: perspectives from EAE. Curr. Pharm. Des. 2005, 11:1031-1037.
225. Williams R.O. Therapeutic effect of vasoactive intestinal peptide in collagen-induced arthritis. Arthritis Rheum. 2002, 46:271-273.
226. Xin Z., Sriram S. Vasoactive intestinal peptide inhibits IL-12 and nitric oxide production in murine macrophages. J. Neuroimmunol. 1998, 89:206-212.
227. Yamamoto M., Yoshizaki K., Kishimoto T., Ito H. IL-6 is required for the development of Th1 cell-mediated murine colitis. J. Immunol. 2000, 164:4878-4882.
228. Yin H., Cheng H., Yu M., Zhang F., Lin J., Gao Y., Han B., Zhu L. Vasoactive intestinal peptide ameliorates synovial cell functions of collagen-induced arthritis rats by downregulating NF-kappaB activity. Immunol. Invest. 2005, 34:153-169.
229. Yin Q., Kemp G.J., Frostick S.P. Neurotrophins, neurones and peripheral nerve regeneration. J. Hand Surg. [Br] 1998, 23:433-437.
230. Yong V.W. Differential mechanisms of action of interferonbeta and glutiramer acetate in MS. Neurology 2002, 59:802-808.
231. Zhang P., Hogan E.L., Bhat N.R. Activation of JNK/ SAPK in primary glial cultures: II. Differential activation of kinase isoforms corresponds to their differential expression. Neurochem. Res. 1998, 23:219-225.
232. Zhong H., Voll R.E., Ghosh S. Phosphorylation of NFkappa B p65by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/ p300. Mol. Cell. 1998, 1:661-671.
233. Zlotnik A., Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000, 12:121-127.